Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609592 · ClinicalTrials.gov registry record · Phase 1
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
A Phase 1 study of Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04609592: Recruiting Phase 1 study of Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Stanford University.
NCT04609592 is a Phase 1 study of Gastroenteropancreatic Neuroendocrine Tumor that is actively recruiting participants, run by Stanford University. The registered enrollment target is 10 participants, below the 630-participant average among 5 other Gastroenteropancreatic Neuroendocrine Tumor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04609592, a Phase 1 study of Gastroenteropancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
Conditions Studied
Interventions
- DRUG Lutathera
- DRUG Gallium 68 Dotatate
- PROCEDURE Computed Tomography (CT)
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE PET/CT
Study Locations (1)
California
- Stanford Cancer Institute Palo Alto - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04609592
The ClinicalTrials.gov registry entry for NCT04609592 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 630-participant average among 5 other Gastroenteropancreatic Neuroendocrine Tumor trials with a reported enrollment target (98% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroenteropancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 5 interventions - of which Lutathera is the first listed.
NCT04609592 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04609592 about?
NCT04609592 is a clinical study titled "Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery". The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use be...
What is the current status of trial NCT04609592?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-03-17. Estimated completion is 2027-09.
What conditions does trial NCT04609592 study?
This clinical trial studies the following conditions: Gastroenteropancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT04609592?
The interventions under investigation include: Lutathera (DRUG), Gallium 68 Dotatate (DRUG), Computed Tomography (CT) (PROCEDURE), Magnetic Resonance Imaging (MRI) (PROCEDURE), PET/CT (PROCEDURE).
Who is sponsoring clinical trial NCT04609592?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04609592 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroenteropancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
RECRUITING · Phase 1
-
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 1
-
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
RECRUITING
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
-
Neuroendocrine Tumors - Patient Reported Outcomes
ACTIVE NOT RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.